Aerovate Therapeutics Inc Cash Flow Conversion Efficiency
Aerovate Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) has a cash flow conversion efficiency ratio of -0.032x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($75.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aerovate Therapeutics Inc (2019–2024)
Cash flow conversion efficiency of Aerovate Therapeutics Inc from 2019 to 2024. This chart illustrates how Aerovate Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Aerovate Therapeutics Inc stock price today for real-time trading data and today's change.
Aerovate Therapeutics Inc Cash Flow Conversion Ratio Explained
Aerovate Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aerovate Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aerovate Therapeutics Inc ranked by their cash flow conversion efficiency. Also see AVTE market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dong Yang Pipe
KO:008970
|
-0.111x |
|
PolyPid
NASDAQ:PYPD
|
-2.876x |
|
Cufe Ltd
AU:CUF
|
-0.110x |
|
Manba Finance Ltd
NSE:MANBA
|
-0.483x |
|
Asetek A/S
F:A31
|
0.018x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-0.191x |
|
Delta Djakarta Tbk
JK:DLTA
|
0.097x |
|
Wintergreen Acquisition Corp. Ordinary Shares
NASDAQ:WTG
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Aerovate Therapeutics Inc from 2019 to 2024. Review Aerovate Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | -126.98% |
| 2020-12-31 | $-13.34 Million | $-7.86 Million | 0.589x | -22.85% |
| 2019-12-31 | $-3.64 Million | $-2.78 Million | 0.763x | -- |
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.